Med Spa M&A in 2025-2026: Valuations, Deal Structures, and What’s Next
Private equity investment in medical spas remained disciplined in 2025, with add-on acquisitions dominating over headline deals and valuations ranging from 3x to 6x EBITDA for smaller practices to 7x to 12x EBITDA for regional platforms exceeding $20M revenue. Deal structures typically split 60 to 80 percent cash at close with 20 to 40 percent rollover equity, with holdbacks common where provider retention or growth execution is uncertain. The 2026 market is closely watching the recapitalization cycle of major PE-backed medspa platforms, which could trigger renewed acquisition intensity and upward multiple pressure across the sector. Buyers now prioritize recurring revenue, EBITDA margins, clean financial reporting, and teams that operate independently of a single owner. Compliance documentation around scope of practice and MSO structures has become a deal prerequisite. Written by Tommy Newton, Principal, Xite.
For medspa operators and PE sponsors tracking the aesthetics rollup market, the pending recapitalization of major platforms in 2026 could reset valuation benchmarks and deal pace across the sector. Understanding current deal structure norms is essential for operators considering a partnership or exit process.
Use it for: A starting range for med spa sale conversations. The author, a principal at advisory firm Xite, puts practices under $4M in revenue at 3x–6x EBITDA, $4M–$20M at 5x–8x and over $20M at 7x–12x, with roughly 60–80% cash at close and 20–40% rollover equity.
Watch out for: These are one advisor’s ranges published by AmSpa, not a transaction dataset. The author ties a strong 2026 to recapitalizations unfolding as anticipated and capital remaining accessible. Scope-of-practice, injectable supervision and MSO compliance gaps can lower an offer or stall a deal.
Try this: Run your EBITDA through the HGS valuation calculator at the low and high end of your revenue band, then decide which holdbacks or earnouts you would accept.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.
What are current med spa M&A valuations in 2025–2026?
Smaller medical spa practices are trading at 3x to 6x EBITDA, while regional platforms with more than $20 million in annual revenue command 7x to 12x EBITDA. Deal structures typically include 60 to 80 percent cash at close with 20 to 40 percent rollover equity, with holdbacks common where provider retention or revenue targets are uncertain.
What is driving private equity investment in medical spas?
PE firms are attracted to medical spas by recurring membership revenue, scalable service menus, low clinical overhead relative to traditional healthcare, and an expanding consumer base. Add-on acquisitions dominate as platforms build regional density before seeking recapitalization at higher multiples.
What should med spa owners evaluate before accepting a PE partnership offer?
Owners should scrutinize rollover equity terms, earnout structures, and how the ongoing PE recapitalization cycle affects future enterprise value. With major medspa platforms entering recap cycles in 2026, timing and deal structure often matter more than headline EBITDA multiples.